Biogen publishes adolescent Phase 3 EMPAVELI subgroup results
Biogen said it has published a prespecified adolescent subgroup analysis from its Phase 3 VALIANT study of EMPAVELI (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.